{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:38:48Z","timestamp":1792251528389,"version":"4.4.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1097\/mjt.0b013e3181c0695e","type":"journal-article","created":{"date-parts":[[2010,3,24]],"date-time":"2010-03-24T08:15:25Z","timestamp":1269418525000},"page":"255-262","source":"Crossref","is-referenced-by-count":19,"title":["Statins in Hypertension: Are They a New Class of Antihypertensive Agents?"],"prefix":"10.1097","volume":"17","author":[{"given":"Carlos A","family":"Feldstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210202","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archinte.159.10.1104","article-title":"Clustering of metabolic factors and coronary heart disease.","volume":"159","author":"Wilson","year":"1999","journal-title":"Arch Intern Med"},{"key":"R2-6-20210202","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories.","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"R3-6-20210202","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1001\/archinte.1992.00400190110021","article-title":"Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group.","volume":"152","author":"Neaton","year":"1992","journal-title":"Arch Intern Med"},{"key":"R4-6-20210202","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1001\/archinte.167.22.2431","article-title":"Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004.","volume":"167","author":"Wong","year":"2007","journal-title":"Arch Intern Med"},{"key":"R5-6-20210202","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/1074248407300380","article-title":"Do statins lower blood pressure.","volume":"12","author":"Mangat","year":"2007","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"key":"R6-6-20210202","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1161\/01.HYP.34.4.987","article-title":"State-of-the-art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action.","volume":"34","author":"Faggiotto","year":"1999","journal-title":"Hypertension"},{"key":"R7-6-20210202","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00041433-199912000-00010","article-title":"Low-density lipoprotein-independent effects of statins.","volume":"10","author":"Davignon","year":"1999","journal-title":"Curr Opin Lipidol"},{"key":"R8-6-20210202","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2174\/138161206776843313","article-title":"Is hypertension an inflammatory process?","volume":"12","author":"Boos","year":"2006","journal-title":"Curr Pharm Des"},{"key":"R9-6-20210202","first-page":"2945","article-title":"C-reactive protein and the risk of developing hypertension JAMA.","volume":"290","author":"Sesso","year":"2003","journal-title":""},{"key":"R10-6-20210202","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1524-6175.2004.03577.x","article-title":"Elevation of C-reactive protein in people with hypertension.","volume":"6","author":"King","year":"2004","journal-title":"J Clin Hypertens"},{"key":"R11-6-20210202","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0140-6736(95)90345-3","article-title":"Hyperlipidaemia, hypertension and coronary heart disease.","volume":"345","author":"Goode","year":"1995","journal-title":"Lancet"},{"key":"R12-6-20210202","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0735-1097(98)00514-2","article-title":"Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions.","volume":"33","author":"Kaesemeyer","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"R13-6-20210202","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/01.CIR.100.21.2131","article-title":"Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men.","volume":"100","author":"Nickenig","year":"1999","journal-title":"Circulation"},{"key":"R14-6-20210202","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1006\/jmcc.2001.1421","article-title":"Endothelin-1 synthesis and endothelin B receptor expression in human coronary artery smooth muscle cells and monocyte-derived macrophages is up-regulated by low density lipoproteins.","volume":"33","author":"Haug","year":"2001","journal-title":"J Mol Cell Cardiol"},{"key":"R15-6-20210202","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/01.HYP.37.6.1450","article-title":"HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species.","volume":"37","author":"Wassmann","year":"2001","journal-title":"Hypertension"},{"key":"R16-6-20210202","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0895-7061(01)02210-5","article-title":"Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia.","volume":"14","author":"Leibovitz","year":"2001","journal-title":"Am J Hypertens"},{"key":"R17-6-20210202","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0735-1097(02)01717-5","article-title":"Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension.","volume":"39","author":"Ferrier","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R18-6-20210202","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.HYP.0000024348.87637.6F","article-title":"Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress.","volume":"40","author":"Delbosc","year":"2002","journal-title":"Hypertension"},{"key":"R19-6-20210202","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.amjhyper.2007.03.018","article-title":"Use of statins and blood pressure.","volume":"20","author":"King","year":"2007","journal-title":"Am J Hypertens"},{"key":"R20-6-20210202","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0021-9150(96)05834-0","article-title":"Impaired radial artery compliance in normotensive subjects with familial hypercholesterolemia.","volume":"124","author":"Giannattasio","year":"1996","journal-title":"Atherosclerosis"},{"key":"R21-6-20210202","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF00198301","article-title":"Does lowering of cholesterol levels influence functional properties of large arteries?","volume":"48","author":"Kool","year":"1995","journal-title":"Eur J Clin Pharmacol"},{"key":"R22-6-20210202","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1046\/j.1365-2796.1998.00350.x","article-title":"Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle-aged men free from cardiovascular disease.","volume":"244","author":"Bak","year":"1998","journal-title":"J Intern Med"},{"key":"R23-6-20210202","first-page":"108","article-title":"Effect of plasma cholesterol reduction by pravastatin on the functional properties of forearm arteries in hypercholesterolemic patients.","volume":"9","author":"Baldassarre","year":"1999","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R24-6-20210202","first-page":"272","article-title":"Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin). A pilot study.","volume":"128","author":"Abetel","year":"1998","journal-title":"Schweiz Med Wochenschr"},{"key":"R25-6-20210202","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(99)80621-3","article-title":"Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension.","volume":"75","author":"Straznicky","year":"1995","journal-title":"Am J Cardiol"},{"key":"R26-6-20210202","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1161\/01.HYP.34.6.1281","article-title":"Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.","volume":"34","author":"Glorioso","year":"1999","journal-title":"Hypertension"},{"key":"R27-6-20210202","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S0002-9149(99)00132-0","article-title":"Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril).","volume":"83","author":"Sposito","year":"1999","journal-title":"Am J Cardiol"},{"key":"R28-6-20210202","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.amjhyper.2004.02.002","article-title":"Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs.","volume":"17","author":"Ikeda","year":"2004","journal-title":"Am J Hypertens"},{"key":"R29-6-20210202","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/08037059409102294","article-title":"Short term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients.","volume":"3","author":"OCallaghan","year":"1994","journal-title":"Blood Press"},{"key":"R30-6-20210202","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/028134399750002764","article-title":"Treatment of hypertensive and hypercholesterolaemic patients in general practice. The effect of captopril, atenolol and pravastatin combined with life style intervention.","volume":"17","author":"Foss","year":"1999","journal-title":"Scand J Prim Health Care"},{"key":"R31-6-20210202","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/sj.jhh.1001786","article-title":"Long-term effects of statins on arterial pressure and stiffness of hypertensives.","volume":"19","author":"Ichihara","year":"2005","journal-title":"J Hum Hypertens"},{"key":"R32-6-20210202","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1161\/01.CIR.0000143085.86697.13","article-title":"Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients.","volume":"110","author":"Koh","year":"2004","journal-title":"Circulation"},{"key":"R33-6-20210202","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00004872-200101000-00011","article-title":"Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima-media thickness in the moderately hypercholesterolaemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. PHYLLIS study group.","volume":"19","author":"Zanchetti","year":"2001","journal-title":"J Hypertens"},{"key":"R34-6-20210202","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/01.fjc.0000175432.56789.e6","article-title":"Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors.","volume":"46","author":"Terzoli","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"R35-6-20210202","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1081\/JDI-56610","article-title":"Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients.","volume":"27","author":"Kanbay","year":"2005","journal-title":"Ren Fail"},{"key":"R36-6-20210202","first-page":"742","article-title":"Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control.","volume":"6","author":"Magen","year":"2004","journal-title":"Isr Med Assoc J"},{"key":"R37-6-20210202","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.amjcard.2007.02.085","article-title":"Effects of valsartan alone versus valsartan\/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension.","volume":"100","author":"Rajagopalan","year":"2007","journal-title":"Am J Cardiol"},{"key":"R38-6-20210202","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ahj.2004.02.003","article-title":"Brisighella Heart Study Working Party. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study.","volume":"148","author":"Borghi","year":"2004","journal-title":"Am Heart J"},{"issue":"Suppl III","key":"R39-6-20210202","first-page":"402","article-title":"Statins lower blood pressure: results from the UCSD statin study.","volume":"110","author":"Golomb","year":"2004","journal-title":"Circulation"},{"key":"R40-6-20210202","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Poulter NR, et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"R41-6-20210202","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ALLHAT-LLT Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"R42-6-20210202","first-page":"407","article-title":"Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience.","volume":"12","author":"Velussi","year":"1999","journal-title":"Diabetes Nutr Metab"},{"key":"R43-6-20210202","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1046\/j.1365-2362.2000.00735.x","article-title":"Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients.","volume":"30","author":"Tonolo","year":"2000","journal-title":"Eur J Clin Invest"},{"key":"R44-6-20210202","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1161\/01.HYP.0000166722.91714.ba","article-title":"Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes.","volume":"45","author":"Koh","year":"2005","journal-title":"Hypertension"},{"key":"R45-6-20210202","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1161\/01.HYP.0000259737.43916.42","article-title":"Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials.","volume":"49","author":"Strazzullo","year":"2007","journal-title":"Hypertension"},{"key":"R46-6-20210202","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.amjcard.2007.08.033","article-title":"Impact of systemic hypertension on the cardiovascular benefits of statin therapy--a meta-analysis.","volume":"101","author":"Messerli","year":"2008","journal-title":"Am J Cardiol"},{"key":"R47-6-20210202","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3109\/07853890008995944","article-title":"Angiotensin AT1 receptor over-expression in hypercholesterolaemia.","volume":"32","author":"Strehlow","year":"2000","journal-title":"Ann Med"},{"key":"R48-6-20210202","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1161\/01.ATV.19.11.2769","article-title":"Coronary endothelial function is preserved with chronic endothelin receptor antagonism in experimental hypercholesterolemia in vitro.","volume":"19","author":"Best","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R49-6-20210202","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/01.ATV.0000254855.24394.f9","article-title":"Pravastatin enhances beneficial effects of olmesartan on vascular injury of salt-sensitive hypertensive rats, via pleiotropic effects.","volume":"27","author":"Yamamoto","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R50-6-20210202","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.HYP.0000136395.06810.cf","article-title":"Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress.","volume":"44","author":"Zhou","year":"2004","journal-title":"Hypertension"},{"key":"R51-6-20210202","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1161\/01.ATV.0000163840.63685.0c","article-title":"Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.","volume":"25","author":"Arnaud","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R52-6-20210202","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM199602083340607","article-title":"Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system.","volume":"334","author":"Reaven","year":"1996","journal-title":"N Engl J Med"},{"key":"R53-6-20210202","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/MED.0b013e3282f7026f","article-title":"The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control.","volume":"15","author":"Perkins","year":"2008","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R54-6-20210202","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00228-006-0176-1","article-title":"Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients.","volume":"62","author":"Fogari","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"R55-6-20210202","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archinte.165.10.1147","article-title":"Predictors of adherence with antihypertensive and lipid-lowering therapy.","volume":"165","author":"Chapman","year":"2005","journal-title":"Arch Intern Med"},{"key":"R56-6-20210202","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4065\/83.1.35","article-title":"Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine\/atorvastatin in African Americans: the CAPABLE trial.","volume":"83","author":"Flack","year":"2008","journal-title":"Mayo Clin Proc"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0b013e3181c0695e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:35:10Z","timestamp":1620963310000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201005000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e3181c0695e","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}